Literature DB >> 7561616

Glucagon-like peptide-1 binding to rat hepatic membranes.

M L Villanueva-Peñacarrillo1, E Delgado, M A Trapote, A Alcántara, F Clemente, M A Luque, A Perea, I Valverde.   

Abstract

We have found [125I]glucagon-like peptide (GLP)-1(7-36)amide specific binding activity in rat liver and isolated hepatocyte plasma membranes, with an M(r) of approximately 63,000, estimated by cross-linking and SDS-PAGE. The specific binding was time- and membrane protein concentration-dependent, and equally displaced by unlabelled GLP-1(7-36)amide and by GLP-1(1-36)amide, achieving its ID50 at 3 x 10(-9) M of the peptides. GLP-1(7-36)amide did not modify the basal or the glucagon (10(-8) M)-stimulated adenylate cyclase in the hepatocyte plasma membranes. These data, together with our previous findings of a potent glycogenic effect of GLP-1(7-36)amide in isolated rat hepatocytes, led us to postulate that the insulin-like effects of this peptide on glucose liver metabolism could be mediated by a type of receptor probably different from that described for GLP-1 in pancreatic B-cells or, alternatively, by the same receptor which, in this tissue as well as in muscle, uses a different transduction system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561616     DOI: 10.1677/joe.0.1460183

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  18 in total

1.  GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.

Authors:  C G Jolivalt; M Fineman; C F Deacon; R D Carr; N A Calcutt
Journal:  Diabetes Obes Metab       Date:  2011-11       Impact factor: 6.577

Review 2.  Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling.

Authors:  Charlotte C Ronveaux; Daniel Tomé; Helen E Raybould
Journal:  J Nutr       Date:  2015-02-04       Impact factor: 4.798

Review 3.  Targeting the CNS to treat type 2 diabetes.

Authors:  Darleen A Sandoval; Silvana Obici; Randy J Seeley
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

4.  Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver.

Authors:  M A Trapote; F Clemente; C Galera; M Morales; A I Alcántara; M I López-Delgado; M L Villanueva-Peñacarrillo; I Valverde
Journal:  J Endocrinol Invest       Date:  1996-02       Impact factor: 4.256

5.  Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.

Authors:  M L Villanueva-Peñacarrillo; J Puente; A Redondo; F Clemente; I Valverde
Journal:  Endocrine       Date:  2001-07       Impact factor: 3.633

Review 6.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

Authors:  K Pabreja; M A Mohd; C Koole; D Wootten; S G B Furness
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

7.  Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis.

Authors:  Eva Tomas; Joel F Habener
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

8.  Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.

Authors:  Dale S Edgerton; Zhibo An; Kathryn M S Johnson; Tiffany Farmer; Ben Farmer; Doss Neal; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-05-14       Impact factor: 4.310

9.  Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process.

Authors:  Vered Aviv; Irit Meivar-Levy; Itzhak H Rachmut; Tamar Rubinek; Eytan Mor; Sarah Ferber
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

10.  Incretin concepts.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.